FDA Review Of Novartis’ Tekturna Set Back Three Months

Delay will allow agency to review new data on the impact of the first-in-class blood pressure medication on the colon.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet